This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 2 of 2 for:    pt-112

An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2016 by SciClone Pharmaceuticals ( SciClone Pharmaceuticals International (Cayman) Development Limited )
Sponsor:
Collaborators:
Parexel
National Cheng-Kung University Hospital
Information provided by (Responsible Party):
SciClone Pharmaceuticals ( SciClone Pharmaceuticals International (Cayman) Development Limited )
ClinicalTrials.gov Identifier:
NCT02884479
First received: August 17, 2016
Last updated: September 20, 2016
Last verified: September 2016
  Purpose
The purpose of this study is to test PT-112 in Combination with Docetaxel in Subjects with Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects with Non-Small Cell Lung Cancer.

Condition Intervention Phase
Advanced Solid Tumor Non-Small Cell Lung Cancer Drug: PT-112 Drug: Docetaxel Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study

Resource links provided by NLM:


Further study details as provided by SciClone Pharmaceuticals ( SciClone Pharmaceuticals International (Cayman) Development Limited ):

Primary Outcome Measures:
  • dose-limiting toxicities (DLTs) [ Time Frame: Day 0 to Day 28 ]
  • area under the plasma concentration-time curve from 0 to the last measurable concentration (AUClast) [ Time Frame: Cycle 1, Day 1: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 5, 8, 12, 24 hours post dose Cycle 1, Day 8: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24 hours post dose Cycle 2, Day 8: Pre-dose, 1, 2, 4 hours post dose Cycle 3 & 4, Day 8: Pre-dose ]

Secondary Outcome Measures:
  • Adverse Events [ Time Frame: Cycle 1: Day 1, Day 8, Day 15; Cycle 2: Day 1, Day 8; Follow up: 30 days post final dose ]

Estimated Enrollment: 75
Study Start Date: August 2016
Estimated Study Completion Date: March 2019
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PT-112 + Docetaxel
Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
Drug: PT-112
Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
Drug: Docetaxel
Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.

  Eligibility

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  1. Male or female ≥ 20 years of age on the day of signing informed consent.
  2. Subjects with advanced tumor of any histological type and meet the following eligibility criteria for the corresponding part of the study:

    • In Part 1, the subjects who failed at least one prior therapy must have pathologically confirmed advanced solid tumor of any histological type with preference of subjects with advanced NSCLC and either no available, or intolerable to, standard of-care treatment.
    • In Part 2, the subjects must have pathologically confirmed advanced NSCLC. Subjects are required to have evidence of measurable disease per RECIST v1.1.
  3. Eastern Collaborative Oncology Group (ECOG) Performance Status ≤ 1.
  4. Subject must have adequate organ function as indicated by the following laboratory values:

    • Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.
    • Platelets ≥ 100 × 109/L.
    • Hemoglobin ≥ 90 g/L or 5.6 mmol/L.
    • Serum creatinine ≤ 1.5 × upper limit of normal (ULN), or calculated or directly measured creatinine clearance ≥ 60% lower limit of normal (LLN).
    • Serum total bilirubin ≤ 1.5 × ULN (subjects with Gilbert's Syndrome are allowed if direct bilirubin is within normal limits).
    • Aspartate aminotransferase (AST [SGOT]) and/or alanine aminotransferase (ALT [SGPT]) ≤ 2.5 × ULN, or ≤ 5 × ULN in presence of liver metastases.
    • International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN.
    • Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.
    • Albumin ≥ 3 mg/dL.
  5. Female subjects are eligible to enter and participate in the study if they are of:

    • Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who
    • has had a hysterectomy
    • has had a bilateral oophorectomy (ovariectomy)
    • has had a bilateral tubal ligation
    • is post-menopausal (total cessation of menses for ≥ 1 year)
    • Childbearing potential, have a negative serum pregnancy test at screening (within 7 days of the first investigational product administration), are not breast feeding, and use adequate contraception before study entry and throughout the study until 180 days after the last investigational product administration. Adequate contraception, when used consistently and in accordance with both the product label and the instructions of the physician, are defined as follows:
    • Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
    • Any intra-uterine device with a documented failure rate of less than 1% per year.
    • Double barrier contraception defined as condom with spermicidal jelly, foam, suppository, or film; or diaphragm with spermicide; or male condom and diaphragm.
  6. Male subjects are eligible to enter and participate in the study if they are vasectomized or agree to use of contraception during the study treatment period and for at least 180 days after the last dose of the study drug.
  7. Willing and able to provide written informed consent and comply with the requirements of the study.

Exclusion Criteria:

  • Subjects meeting any of the following criteria are ineligible for participation in the study:

    1. Any cytotoxic chemotherapy within 21 days, prior to initiation of study drug.
    2. Receipt of more than three prior regimens of cytotoxic chemotherapy (immunotherapy and targeted therapy will not be counted as a line of therapy).
    3. History of hypersensitivity reaction to docetaxel and polysorbate 80 or any of its components.
    4. Presence of an acute or chronic toxicity of prior chemotherapy, with the exception of alopecia, that has not resolved to Grade 1, as determined by National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03.
    5. Evidence of peripheral neuropathy of Grade 2 or greater within 28 days prior to initiation of dosing.
    6. Symptomatic brain metastasis requiring active treatment.
    7. Bone marrow reserve which, in the clinical judgment of the Principal Investigator, is not adequate for participation in this study.
    8. Known allergy or hypersensitivity to Pt-containing agents, or known intolerance to a prior Pt-containing agent which, in the judgment of the Principal Investigator, precludes re-exposure to a Pt-containing agent.
    9. Radiotherapy within 28 days prior to baseline and/or receipt of radiotherapy to >25 % of bone marrow volume.
    10. Major surgery within 28 days prior to initiation of study drug combination.
    11. Life expectancy <12 weeks.
    12. Active or clinically unstable bacterial, viral, or fungal infection requiring systemic therapy.
    13. Known human immunodeficiency virus or acquired immunodeficiency syndrome-related illness.
    14. Clinically significant hearing impairment, as judged by the Principal Investigator.
    15. Any of the following within 3 months prior to initiation of study drug: uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4, APPENDIX 2), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism.
    16. Unstable cardiac dysrhythmias or persistent prolongation of the QTc (Fridericia) interval to >450 msec for males or >470 msec for females.
    17. In Part 2, any previous malignancy, except for non squamous-cell carcinoma of skin or carcinoma-in-situ of the uterine cervix, unless the tumor was successfully treated with curative intent more than two years prior to study entry.
    18. Use of any investigational agents within 28 days prior to the screening.
    19. Pregnant or lactating female.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02884479

Contacts
Contact: Crystal Qin, M.D, Ph.D 86-21-2319 3802 cqin@sciclone.com

Locations
Taiwan
Changhua Christian Hospital Recruiting
Changhua County, Taiwan
Contact: Chien-Te Li         
Principal Investigator: Chien-Te Li         
China Medical University & Hospital Not yet recruiting
Taichung, Taiwan
Contact: Te-Chun Hsia         
Principal Investigator: Te-Chun Hsia         
National Cheng Kung University Hospital Recruiting
Tainan City, Taiwan
Contact: Wu-Chou Su         
Principal Investigator: Wu-Chou Su         
Tri-Service General Hospital Recruiting
Taipei City, Taiwan
Contact: Ching-Lian Ho         
Principal Investigator: Ching-Lian Ho         
Sponsors and Collaborators
SciClone Pharmaceuticals International (Cayman) Development Limited
Parexel
National Cheng-Kung University Hospital
Investigators
Principal Investigator: Wu-Chou Su National Cheng-Kung University Hospital
  More Information

Responsible Party: SciClone Pharmaceuticals International (Cayman) Development Limited
ClinicalTrials.gov Identifier: NCT02884479     History of Changes
Other Study ID Numbers: SCI-PT112-ONC-P1-001
Study First Received: August 17, 2016
Last Updated: September 20, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 18, 2017